|drug2912||Pipeline™ Flex Embolization Device with Shield Technology™ Wiki||1.00|
|drug513||Bariatric surgery Wiki||1.00|
|D017542||Aneurysm, Ruptured NIH||1.00|
|D002532||Intracranial Aneurysm NIH||1.00|
There is one clinical trial.
The purpose of the study is to assess the safety and effectiveness of the Pipeline™ Flex Embolization Device with Shield Technology™ in the treatment with acutely ruptured intracranial aneurysms.
Description: Occlusion is measured by the Raymond Roy Scale. Significant stenosis is classified as >50%.Measure: Incidence of complete angiographic occlusion without significant stenosis, and no rebleeding or retreatment of the target aneurysm Time: at 180-day
Description: Disabling stroke is defined as any post-procedural ischemic or hemorrhagic event that results in poor functional outcome (i.e. mRS ≥ 3 points) assessed at 90 days post stroke event through 180 day follow-up.Measure: Incidence of neurological death or disabling stroke post-procedure. Time: at 180-day
Description: Scale for measuring general neurologic function: 0- No symptoms at all No significant disability despite symptoms; able to carry out all usual duties and activities Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance Moderate disability; requiring some help, but able to walk without assistance Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance Severe disability; bedridden, incontinent and requiring constant nursing care and attention DeadMeasure: Good clinical outcome (modified Rankin Scale (mRS) 0-2) Time: at 30-day, 180-day and 365-day post procedure
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports